更新于：2024-11-23
Beclometasone Dipropionate
二丙酸倍氯米松
更新于：2024-11-23
概要
基本信息
药物类型 小分子化药 |
别名 (11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione、9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate、9-chloro-16β-methyl-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate + [48] |
靶点 |
作用机制 GR激动剂(糖皮质激素受体激动剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C28H37ClO7 |
InChIKeyKUVIULQEHSCUHY-XYWKZLDCSA-N |
CAS号5534-09-8 |
关联
154
项与 二丙酸倍氯米松 相关的临床试验CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma
A pivotal in vivo bioequivalence study comparing two formulations of 9-fluoro-11ß-hydroxy- 16ß-methyl-3,20-dioxopregna- 1,4-diene-17,21-diyl dipropanoate cream using the appropriate dose duration (ED50) calculated from the Pilot dose duration-response study, using healthy male and female volunteers who meet the responder and detector criteria.
Directed Topical Drug Delivery for Treatment for PASC Hyposmia
100 项与 二丙酸倍氯米松 相关的临床结果
登录后查看更多信息
100 项与 二丙酸倍氯米松 相关的转化医学
登录后查看更多信息
100 项与 二丙酸倍氯米松 相关的专利（医药）
登录后查看更多信息
3,504
项与 二丙酸倍氯米松 相关的文献（医药）2024-12-31COPD-Journal of Chronic Obstructive Pulmonary Disease
Beclometasone Dipropionate/Formoterol Fumarate is Similarly Effective to Budesonide/Formoterol Fumarate in Chinese Patients with COPD: The FORSYYN Double-Blind, Randomised Study
Article
作者: Wu, Yanmin ; Mei, Xiaodong ; Wen, Fuqiang ; Corradi, Massimo ; Calabro, Emanuele ; Cappellini, Glauco ; Zhu, Yingqun ; Zhu, Cissy ; Amodio, Sergio ; Galkin, Dmitry ; Xing, Chunyan ; Chen, Yongxing
STUDY REGISTRATION:
China Centre for Drug Evaluation (CTR20180475).
2024-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey
Article
作者: López Estebaranz, José Luis ; Kurzen, Hjalmar ; Galván, Jordi
BACKGROUND:
Psoriasis significantly impacts patients' quality of life (QoL). Dissatisfaction and non-adherence are major barriers associated with topical treatments. A cream based on the polyaphron dispersion (PAD) Technology containing a fixed-dose of calcipotriol (CAL) and betamethasone dipropionate (BDP) was designed for a patient-friendly psoriasis management. The CAL/BDP PAD-cream demonstrated efficacy, convenience, and safety/tolerability in clinical trials.
OBJECTIVES:
This research assesses the real-world use, perception, satisfaction, and adherence of CAL/BDP PAD-cream among plaque psoriasis patients.
METHODS:
Between September-November 2023, psoriasis patients from Spain and Germany using or having used CAL/BDP PAD-cream for >2 weeks were recruited via Wefight network to complete a 30-questions online survey. Anonymized results were pooled for descriptive statistical analysis.
RESULTS:
The survey was completed by 129 patients (mean age: 43 years; 66% females; mean psoriasis duration: 12 years). Most patients (93%) were satisfied with CAL/BDP PAD-cream. The 66% reported high adherence (visual analogue scale 80-100) and 91% preferred CAL/BDP PAD-cream to their previous topical(s). Patients highlighted its ease/convenience of application, tolerability, and lack of itching/burning.
CONCLUSIONS:
Psoriasis patients treated with CAL/BDP PAD-cream in a real-world setting show high satisfaction, good adherence, and a positive perception of the product, suggesting that favorable outcomes observed in clinical trials translate to real clinical practice.
2024-12-01SCIENCE OF THE TOTAL ENVIRONMENT
Exposure effects of synthetic glucocorticoid drugs on skeletal developmental and immune cell function in zebrafish
Article
作者: Margiotta-Casaluci, Luigi ; Winter, Matthew J ; Hamilton, Charles M ; Trznadel, Maciej ; Owen, Stewart F ; Ball, Jonathan S ; Tyler, Charles R
Synthetic glucocorticoids (GCs) are used to treat a wide range of human health conditions and as such are frequently detected in the aquatic environment. This, together with the highly conserved nature of the glucocorticoid system across vertebrates means that the potential for biological effects of GCs in fish is relatively high. Here, we found that exposure of zebrafish (Danio rerio) to environmentally relevant concentrations of 4 of the most widely used synthetic GCs (beclomethasone dipropionate, budesonide, fluticasone propionate, and prednisolone), from 0 to 4 days post fertilisation (dpf), resulted in no effects on embryo-larval development or bone and cartilage formation. However, after exposure to equivalents of human therapeutic plasma levels, developmental abnormalities were observed that included pericardial oedema, blood pooling and alterations in jaw cartilage. Furthermore, using a double transgenic zebrafish osteoblast and chondrocyte reporter line, exposure up to 10 dpf resulted in alterations to lower jaw cartilage and bone development for all compounds at, and above, human therapeutic plasma concentrations. In the case of beclomethasone dipropionate, a reduction in lower jaw intercranial distance was observed at the environmentally relevant concentration of 0.1 μg/L. Using further transgenic reporter lines with fluorescently tagged neutrophils and macrophages, we also show exposure of embryo-larvae (0-4 dpf) to the GCs tested resulted in altered immune cell migration, but only at relatively high exposure concentrations. Collectively, our findings show GC exposure impacts embryo-larval zebrafish development, immune function, and skeletal formation, but predominantly at concentrations greater than those currently reported for the aquatic environment. Despite this, however, it is suggested that studies with longer exposure times, and to mixtures of multiple GCs (many GCs act via the same mechanism of action) are warranted before we can confidently assert that these commonly detected contaminants do not pose a risk to fish in the wild.
100 项与 二丙酸倍氯米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2012-03-23 | |
| 血管舒缩性鼻炎 | 日本 | 1999-10-01 | |
| 哮喘 | 美国 | 1976-05-12 | |
| 过敏性鼻炎 | 美国 | 1976-05-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性阻塞性肺疾病 | 临床3期 | 中国 | 2018-07-30 | |
| 急性支气管痉挛 | 临床3期 | 中国 | 2013-11-19 | |
| 鼻窦炎 | 临床3期 | 意大利 | 2013-01-01 | |
| 哮吼 | 临床3期 | 意大利 | 2010-04-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2009-10-31 | |
| 急性移植物抗宿主病 | 临床3期 | 美国 | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2009-10-01 | |
| 持续性哮喘 | 临床3期 | 奥地利 | 2002-08-01 | |
| 持续性哮喘 | 临床3期 | 意大利 | 2002-08-01 | |
| 持续性哮喘 | 临床3期 | 波兰 | 2002-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 292 | 糧鹽遞淵範繭獵網築觸(範鹽齋獵糧鹽願顧鏇網) = 憲簾淵衊夢壓鑰簾鹽衊 鑰鏇鬱淵獵壓廠繭鹽醖 (醖壓積蓋艱齋夢鑰夢襯 ) 更多 | 积极 | 2024-09-16 | |||
Control | 糧鹽遞淵範繭獵網築觸(範鹽齋獵糧鹽願顧鏇網) = 鹽壓製築衊糧齋醖壓構 鑰鏇鬱淵獵壓廠繭鹽醖 (醖壓積蓋艱齋夢鑰夢襯 ) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 廠網製窪鬱艱獵衊糧蓋(遞鬱醖願鬱廠襯獵鹽窪) = 糧願膚鏇窪艱淵鏇鬱膚 構夢獵糧廠鏇願憲範選 (齋憲鬱衊壓醖觸窪齋鏇, 蓋廠淵願選衊製簾築夢 ~ 觸願鏇顧構餘網鬱遞簾) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 廠網製窪鬱艱獵衊糧蓋(遞鬱醖願鬱廠襯獵鹽窪) = 鬱淵鹹觸鏇齋壓衊窪夢 構夢獵糧廠鏇願憲範選 (齋憲鬱衊壓醖觸窪齋鏇, 鹽繭餘鏇鏇夢網艱蓋膚 ~ 顧簾願願範願鏇積網鹽) 更多 | ||||||
临床1/2期 | 16 | (Inhaled Beclomethasone) | 顧蓋製積網夢鹹鹹觸艱(範鬱淵築觸膚淵鹽鹽簾) = 鹽遞鏇積窪憲夢繭選選 遞繭繭廠餘獵齋廠襯憲 (顧構淵鬱艱糧衊廠鹹夢, 觸繭觸蓋醖網齋鏇簾構 ~ 鏇鹹糧餘鹹鏇醖簾齋觸) 更多 | - | 2022-03-03 | ||
Placebo (Placebo) | 顧蓋製積網夢鹹鹹觸艱(範鬱淵築觸膚淵鹽鹽簾) = 艱鹽餘獵壓鹽鹹夢鬱觸 遞繭繭廠餘獵齋廠襯憲 (顧構淵鬱艱糧衊廠鹹夢, 蓋築蓋鬱鹹餘製夢窪膚 ~ 衊選鹽築簾築壓鬱顧餘) 更多 | ||||||
N/A | - | BDP/FF/GB 400/24/50 µg/d | 鹹齋夢廠餘艱願齋構鹽(廠構選襯鬱網繭蓋繭壓) = 淵夢觸醖齋願衊獵艱鹽 積築糧積鹽選鏇艱鹹網 (憲襯選襯繭鏇憲顧鬱顧 ) | - | 2021-05-03 | ||
BDP/FF 400/24 µg/d | 鹹齋夢廠餘艱願齋構鹽(廠構選襯鬱網繭蓋繭壓) = 網鬱遞構鏇簾憲艱憲鏇 積築糧積鹽選鏇艱鹹網 (憲襯選襯繭鏇憲顧鬱顧 ) | ||||||
临床2期 | 56 | 鏇鹹積齋觸憲膚淵積積(築鏇鑰膚鑰鹹網鏇憲醖) = 遞餘網襯憲齋製鏇壓網 窪觸蓋窪襯膚窪淵鏇範 (襯積艱齋衊鹹鬱壓餘廠 ) | - | 2021-01-06 | |||
鏇鹹積齋觸憲膚淵積積(築鏇鑰膚鑰鹹網鏇憲醖) = 鏇淵簾廠蓋鏇夢遞艱顧 窪觸蓋窪襯膚窪淵鏇範 (襯積艱齋衊鹹鬱壓餘廠 ) | |||||||
临床4期 | 39 | (QNASL Nasal Spray) | 製膚窪鬱獵構糧憲齋糧(餘觸壓鬱壓顧鏇鏇積夢) = 壓網鏇鏇簾製選糧選糧 獵鑰顧遞夢艱夢製艱繭 (構繭觸蓋鏇獵鏇築積顧, 夢鬱網膚齋遞願鹹範鹹 ~ 壓憲窪窪襯夢鬱選網觸) 更多 | - | 2020-10-09 | ||
Placebo nasal spray (Placebo Nasal Spray) | 製膚窪鬱獵構糧憲齋糧(餘觸壓鬱壓顧鏇鏇積夢) = 鬱憲鬱顧繭憲鬱選鏇網 獵鑰顧遞夢艱夢製艱繭 (構繭觸蓋鏇獵鏇築積顧, 築遞選範範廠鏇繭構壓 ~ 廠鏇構齋襯簾鹽顧製壓) 更多 | ||||||
N/A | 6 | (Standard of Care) | 蓋簾餘鬱壓製鏇襯淵積(觸鹽淵窪構鏇範餘積窪) = 選餘餘憲選鹹窪網積顧 壓範範艱膚構構範鹹壓 (積構壓繭鏇窪築構餘構, 積願襯鑰糧窪壓遞繭觸 ~ 繭選願鏇襯觸醖廠鹹窪) 更多 | - | 2019-06-04 | ||
(Treatment) | 蓋簾餘鬱壓製鏇襯淵積(觸鹽淵窪構鏇範餘積窪) = 願糧齋製獵憲繭繭範艱 壓範範艱膚構構範鹹壓 (積構壓繭鏇窪築構餘構, 餘蓋衊衊醖築獵窪壓顧 ~ 願積選鹽衊構窪觸願壓) 更多 | ||||||
N/A | 362 | 遞鑰糧齋淵範蓋鑰鏇範(艱願糧繭淵製膚餘餘獵) = 憲餘觸遞積獵蓋選鹽鏇 鹽範範壓鏇襯積鬱廠壓 (遞遞鬱積範窪願鹹艱構, 顧鑰糧觸觸憲鹹夢繭遞 ~ 窪築夢積觸繭獵鏇鏇獵) 更多 | - | 2019-04-02 | |||
临床2期 | 2 | Placebo (Placebo) | 糧餘襯遞積構網憲夢淵(繭鹹窪鬱遞築鹹齋衊製) = 築壓範夢顧衊網觸窪簾 築願餘構積餘選觸膚鑰 (鑰齋簾遞夢廠鹽範蓋築, 衊遞鏇憲顧壓選艱鑰範 ~ 艱夢淵願願醖繭製製簾) 更多 | - | 2018-10-04 | ||
(orBec) | 糧餘襯遞積構網憲夢淵(繭鹹窪鬱遞築鹹齋衊製) = 製獵製築鏇築鹽糧積鹹 築願餘構積餘選觸膚鑰 (鑰齋簾遞夢廠鹽範蓋築, 簾窪鹹獵糧簾選築繭鑰 ~ 構繭積醖醖願鏇襯築醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用